Concepedia

Jeff Mihalic

JM

Statistics

Publications

8

Citations

731

H-Index

8

Active since

2009

Affiliations

Amgen (United States)(Current)

Nurix (United States)

Jeff Mihalic is an author at Amgen (United States) specializing in medicinal chemistry, drug discovery, and drug design.

Publications per year

2009–2024

8

Publications

8

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun, Zhihong Li, Yosup Rew et al. · Journal of Medicinal Chemistry · 2014 · 296 citations · Full text

, , +7

Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction

Xiaoqi Chen, David J. Kopecky, Jeff Mihalic et al. · Journal of Medicinal Chemistry · 2012 · 224 citations · Full text

, , +16

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Daniel Robbins, Mark Noviski, Ying Siow Tan et al. · Journal of Medicinal Chemistry · 2024 · 96 citations · Full text

, , +17

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel Robbins, Aileen Kelly, May Tan et al. · Blood · 2020 · 46 citations

, , +13

Discovery of potent and specific CXCR3 antagonists

Xiaoqi Chen, Jeff Mihalic, Jeff Deignan et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 20 citations · Full text

, , +12

1–5 of 8